文献速递慢性肾脏病肾小球疾病

尿CXCL16与内皮抑素预测晚期糖尿病肾病小管间质纤维化

Urinary chemokine C-X-C motif ligand 16 and endostatin as predictors of tubulointerstitial fibrosis in patients with advanced diabetic kidney disease.
PubMed 文献 · Nephrol Dial Transplant · 2021-01-01

本研究纳入70例经活检证实的孤立性糖尿病肾病患者,检测多种尿炎症细胞因子与趋化因子,评估其与病理特征及肾脏结局的关联。结果显示尿CXCL16和内皮抑素与间质纤维化及肾小管萎缩(IFTA)评分强相关,且高水平患者肾脏进展更快,多因素校正后为不良肾脏结局的独立危险因素。

要点

  • 尿CXCL16和内皮抑素与IFTA评分强相关,可反映纤维化程度。
  • 尿CXCL16和/或内皮抑素较高者肾脏进展显著更快。
  • 多因素校正后,两者升高为不良肾脏结局的独立危险因素。

核心结论

  • 尿CXCL16和内皮抑素可反映晚期糖尿病肾病患者IFTA程度,并作为肾脏结局的生物标志物。

研究设计与样本

  • 单中心研究纳入70例经肾活检证实的孤立性糖尿病肾病患者,采用多重组酶联免疫吸附试验检测尿炎症细胞因子和趋化因子。

主要发现

  • 患者活检时呈晚期DKD,平均eGFR 36.1 mL/min/1.73 m2,平均尿蛋白肌酐比7.8 g/g肌酐。
  • 较高IFTA评分与更差基线eGFR(P < 0.001)和不良肾脏结局(P = 0.002)相关,而肾小球损伤评分无此关联。
  • 尿CXCL16和内皮抑素与IFTA评分强相关(分别为P = 0.001和P < 0.001)。
  • 尿CXCL16和/或内皮抑素较高者肾脏进展显著更快(P < 0.001)。
  • 多因素校正后,尿CXCL16和内皮抑素升高为不良肾脏结局的独立危险因素(95%CI 1.070-3.455,P = 0.029)。

临床怎么用

  • 在晚期糖尿病肾病患者中,可考虑检测尿CXCL16和内皮抑素辅助评估IFTA程度及肾脏预后风险。

局限性

  • 样本量较小(70例),为单中心研究,需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Interstitial fibrosis and tubular atrophy (IFTA) is a well-recognized risk factor for poor renal outcome in patients with diabetic kidney disease (DKD). However, a noninvasive biomarker for IFTA is currently lacking. The purpose of this study was to identify urinary markers of IFTA and to determine their clinical relevance as predictors of renal prognosis. METHODS: Seventy patients with biopsy-proven isolated DKD were enrolled in this study. We measured multiple urinary inflammatory cytokines and chemokines by multiplex enzyme-linked immunosorbent assay in these patients and evaluated their association with various pathologic features and renal outcomes. RESULTS: Patients enrolled in this study exhibited advanced DKD at the time of renal biopsy, characterized by moderate to severe renal dysfunction [mean estimated glomerular filtration rate (eGFR) 36.1 mL/min/1.73 m2] and heavy proteinuria (mean urinary protein:creatinine ratio 7.8 g/g creatinine). Clinicopathologic analysis revealed that higher IFTA scores were associated with worse baseline eGFR (P < 0.001) and poor renal outcome (P = 0.002), whereas glomerular injury scores were not. Among measured urinary inflammatory markers, C-X-C motif ligand 16 (CXCL16) and endostatin showed strong correlations with IFTA scores (P = 0.001 and P < 0.001, respectively), and patients with higher levels of urinary CXCL16 and/or endostatin experienced significantly rapid renal progression compared with other patients (P < 0.001). Finally, increased urinary CXCL16 and endostatin were independent risk factors for poor renal outcome after multivariate adjustments (95% confidence interval 1.070-3.455, P = 0.029). CONCLUSIONS: Urinary CXCL16 and endostatin could reflect the degree of IFTA and serve as biomarkers of renal outcome in patients with advanced DKD.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Lee YH, Kim KP, Park SH, et al. Urinary chemokine C-X-C motif ligand 16 and endostatin as predictors of tubulointerstitial fibrosis in patients with advanced diabetic kidney disease. Nephrol Dial Transplant. 2021. PMID: 31598726. doi:10.1093/ndt/gfz168

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。